A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology

Journal of Nuclear Cardiology

Volumn 25, Issue 1, 2018, Pages 298-319

  Slart, Riemer H J A ^a,b   Glaudemans, Andor W J M ^a   Lancellotti, Patrizio ^c,d   Hyafil, Fabien ^e,f   Blankstein, Ron ^g   Schwartz, Ronald G ^h   Jaber, Wael A ⁱ   Russell, Raymond ^j   Gimelli, Alessia ^k   Rouzet, François ^e   Hacker, Marcus ^l   Gheysens, Olivier ^m,n   Plein, Sven ^o   Miller, Edward J ^p   Dorbala, Sharmila ^g   Donal, Erwan ^q,r   Sciagra, Roberto ^s   Bucerius, Jan ^s   Verberne, Hein J ^s   Lindner, Oliver ^s   Übleis, Christopher ^s   Agostini, Denis ^s   Signore, Alberto ^s   Edvardsen, Thor ^s   Neglia, Danilo ^s   Beanlands, Rob S ^s   Di Carli, Marcelo ^s   Chareonthaitawee, Panithaya ^s   Dilsizian, Vasken ^s   Soman, Prem ^s   Habib, Gilbert ^s   more..

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF TWENTE   (Netherlands)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d Anthea Hospital   (Italy)

^e BICHAT HOSPITAL   (France)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

ⁱ CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^j BROWN UNIVERSITY   (United States)

^k CNR   (Italy)

^l MEDICAL UNIVERSITY OF VIENNA   (Austria)

^m UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁿ DEPARTMENT OF IMAGING AND PATHOLOGY   (Belgium)

^o UNIVERSITY OF LEEDS   (United Kingdom)

^p YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q RENNES UNIVERSITY HOSPITAL   (France)

^r UNIVERSITÉ DE RENNES 1   (France)

^s NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GALLIUM CITRATE GA 67; RADIOISOTOPE;

ARTICLE; CARDIAC SARCOIDOSIS; CARDIOVASCULAR MAGNETIC RESONANCE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; ECHOCARDIOGRAPHY; HEALTH CARE ORGANIZATION; HEART MUSCLE PERFUSION; HUMAN; IMAGE GUIDED BIOPSY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MYOCARDIAL PERFUSION IMAGING; PERFUSION; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; BIOPSY; CARDIOLOGY; CARDIOMYOPATHY; EUROPE; IMAGE PROCESSING; MEDICAL SOCIETY; NUCLEAR MEDICINE; REPRODUCIBILITY; SARCOIDOSIS; UNITED STATES; X-RAY COMPUTED TOMOGRAPHY;

BIOPSY; CARDIOLOGY; CARDIOMYOPATHIES; DIAGNOSTIC IMAGING; ECHOCARDIOGRAPHY; EUROPE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INFLAMMATION; MYOCARDIAL PERFUSION IMAGING; NUCLEAR MEDICINE; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIONUCLIDE IMAGING; REPRODUCIBILITY OF RESULTS; SARCOIDOSIS; SOCIETIES, MEDICAL; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES;

EID: 85041489918     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-017-1043-4     Document Type: Article

References (103)

1. Ungprasert P, Carmona EM, Utz JP, Ryu JH, Crowson CS, Matteson EL. Epidemiology of sarcoidosis 1946–2013: A population-based study. Mayo Clin Proc 2016;91:183-8.
2. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001;164:1885-9.
3. Lynch JP III, Hwang J, Bradfield J, Fishbein M, Shivkumar K, Tung R. Cardiac involvement in sarcoidosis: Evolving concepts in diagnosis and treatment. Semin Respir Crit Care Med 2014;35:372-90.
4. Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med 1995;119:167-72.
5. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: A clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978;58:1204-11.
6. Nelson JE, Kirschner PA, Teirstein AS. Sarcoidosis presenting as heart disease. Sarcoidosis Vasc Diffuse Lung Dis 1996;13:178-82.
7. Kim JS, Judson MA, Donnino R, Gold M, Cooper LT Jr, Prystowsky EN. Cardiac sarcoidosis. Am Heart J 2009;157:9-21.
8. Yazaki Y, Isobe M, Hiroe M, Morimoto S, Hiramitsu S, Nakano T. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001;88:1006-10.
9. Japanese Ministry Health Welfare. Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis Granulomatous Disord (Jpn) 2007;27:89-102.
10. Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS. HRS Expert Consensus Statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11:1305-23.
11. Cardim N, Galderisi M, Edvardsen T, Plein S, Popescu BA, D’andrea A. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: An Expert Consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. Eur Heart J Cardiovasc Imaging 2015;16:280.
12. Cosyns B, Plein S, Nihoyanopoulos P, Smiseth O, Achenbach S, Andrade MJ. European Association of Cardiovascular Imaging (EACVI) position paper: Multimodality imaging in pericardial disease. Eur Heart J Cardiovasc Imaging 2014;16:12-31.
13. Flachskampf FA, Wouters PF, Edvardsen T, Evangelista A, Habib G, Hoffman P. Recommendations for transoesophageal echocardiography: EACVI update 2014. Eur Heart J Cardiovasc Imaging 2014;15:353-65.
14. Lancellotti P, Tribouilloy C, Hagendorff A, Popescu BA, Edvardsen T, Pierard LA. Recommendations for the echocardiographic assessment of native valvular regurgitation: An executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2013;14:611-44.
15. Lang RM, Badano LP, Tsang W, Adams DH, Agricola E, Buck T. EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography. Eur Heart J Cardiovasc Imaging 2012;13:1-46.
16. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16:233-70.
17. Mor-Avi V, Lang RM, Badano LP, Belohlavek M, Cardim NM, Derumeaux G. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE Consensus Statement on methodology and indications endorsed by the Japanese Society of Echocardiography. J Am Soc Echocardiogr 2011;24:277-313.
18. Popescu BA, Stefanidis A, Nihoyannopoulos P, Fox KF, Ray S, Cardim N. Updated standards and processes for accreditation of echocardiographic laboratories from The European Association of Cardiovascular Imaging: An executive summary. Eur Heart J Cardiovasc Imaging 2014;15:1188-93.
19. Aggarwal NR, Snipelisky D, Young PM, Gersh BJ, Cooper LT, Chareonthaitawee P. Advances in imaging for diagnosis and management of cardiac sarcoidosis. Eur Heart J Cardiovasc Imaging 2015;16:949-58.
20. Focardi M, Picchi A, Nikiforakis N, Bargagli E, Fossi A, Maggiorelli C. Assessment of cardiac involvement in sarcoidosis by echocardiography. Rheumatol Int 2009;29:1051-5.
21. Lewin RF, Mor R, Spitzer S, Arditti A, Hellman C, Agmon J. Echocardiographic evaluation of patients with systemic sarcoidosis. Am Heart J 1985;110:116-22.
22. Burstow DJ, Tajik AJ, Bailey KR, DeRemee RA, Taliercio CP. Two-dimensional echocardiographic findings in systemic sarcoidosis. Am J Cardiol 1989;63:478-82.
23. Chiu CZ, Nakatani S, Zhang G, Tachibana T, Ohmori F, Yamagishi M. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol 2005;95:143-6.
24. Jain A, Starek PJ, Delany DL. Ventricular tachycardia and ventricular aneurysm due to unrecognized sarcoidosis. Clin Cardiol 1990;13:738-40.
25. Patel MB, Mor-Avi V, Murtagh G, Bonham CA, Laffin LJ, Hogarth DK. Right heart involvement in patients with sarcoidosis. Echocardiography 2016;33:734-41.
26. Vasaiwala SC, Finn C, Delpriore J, Leya F, Gagermeier J, Akar JG. Prospective study of cardiac sarcoid mimicking arrhythmogenic right ventricular dysplasia. J Cardiovasc Electrophysiol 2009;20:473-6.
27. Degirmenci H, Demirelli S, Arisoy A, Ermis E, Araz O, Bakirci EM. Myocardial deformation and total atrial conduction time in the prediction of cardiac involvement in patients with pulmonary sarcoidosis. Clin Respir J 2017;11:68-77.
28. Joyce E, Ninaber MK, Katsanos S, Debonnaire P, Kamperidis V, Bax JJ. Subclinical left ventricular dysfunction by echocardiographic speckle-tracking strain analysis relates to outcome in sarcoidosis. Eur J Heart Fail 2015;17:51-62.
29. Kul S, Ozcelik HK, Uyarel H, Karakus G, Guvenc TS, Yalcınsoy M. Diagnostic value of strain echocardiography, galectin-3, and tenascin-C levels for the identification of patients with pulmonary and cardiac sarcoidosis. Lung 2014;192:533-42.
30. Orii M, Hirata K, Tanimoto T, Shiono Y, Shimamura K, Yamano T. Myocardial damage detected by two-dimensional speckle-tracking echocardiography in patients with extracardiac sarcoidosis: Comparison with magnetic resonance imaging. J Am Soc Echocardiogr 2015;28:683-91.
31. Saeed IM, Coggins T, Main ML, Bateman TM. Cardiac sarcoidosis with visually normal wall motion: Role of cardiac MRI, FDG PET, and strain echocardiography. Eur Heart J Cardiovasc Imaging 2015;16:1275.
32. Tigen K, Sunbul M, Karaahmet T, Tasar O, Dundar C, Yalcinsoy M. Early detection of bi-ventricular and atrial mechanical dysfunction using two-dimensional speckle tracking echocardiography in patients with sarcoidosis. Lung 2015;193:669-75.
33. Hyodo E, Hozumi T, Takemoto Y, Watanabe H, Muro T, Yamagishi H. Early detection of cardiac involvement in patients with sarcoidosis by a non-invasive method with ultrasonic tissue characterisation. Heart 2004;90:1275-80.
34. Yasutake H, Seino Y, Kashiwagi M, Honma H, Matsuzaki T, Takano T. Detection of cardiac sarcoidosis using cardiac markers and myocardial integrated backscatter. Int J Cardiol 2005;102:259-68.
35. Hourigan LA, Burstow DJ, Pohlner P, Clarke BE, Donnelly JE. Transesophageal echocardiographic abnormalities in a case of cardiac sarcoidosis. J Am Soc Echocardiogr 2001;14:399-402.
36. Nureki S, Miyazaki E, Nishio S, Ehara C, Yamasue M, Ando M. Interventricular septal thickening as an early manifestation of cardiac sarcoidosis. Int Heart J 2014;55:181-3.
37. Yazaki Y, Isobe M, Hayasaka M, Tanaka M, Fujii T, Sekiguchi M. Cardiac sarcoidosis mimicking hypertrophic cardiomyopathy: Clinical utility of radionuclide imaging for differential diagnosis. Jpn Circ J 1998;62:465-8.
38. Skold CM, Larsen FF, Rasmussen E, Pehrsson SK, Eklund AG. Determination of cardiac involvement in sarcoidosis by magnetic resonance imaging and Doppler echocardiography. J Intern Med 2002;252:465-71.
39. Youssef G, Beanlands RS, Birnie DH, Nery PB. Cardiac sarcoidosis: Applications of imaging in diagnosis and directing treatment. Heart 2011;97:2078-87.
40. Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: With emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol 2009;20:578-83.
41. Mehta D, Lubitz SA, Frankel Z, Wisnivesky JP, Einstein AJ, Goldman M. Cardiac involvement in patients with sarcoidosis: Diagnostic and prognostic value of outpatient testing. Chest 2008;133:1426-35.
42. 67Ga scintigraphy in patients with sarcoidosis. J Nucl Med 2006;47:1571-6.
43. 18F-FDG-PET and PET/CT in patients with sarcoidosis: An updated evidence-based review. Acad Radiol 2014;21:675-84.
44. Ahmadian A, Brogan A, Berman J, Sverdlov AL, Mercier G, Mazzini M. Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. J Nucl Cardiol 2014;21:925-39.
45. Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;63:329-36.
46. 18F-fluorodeoxyglucose positron emission tomography: An autopsy case. Circulation 2010;122:535-6.
47. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972-80.
48. Newsholme P, Newsholme EA. Rates of utilization of glucose, glutamine and oleate and formation of end-products by mouse peritoneal macrophages in culture. Biochem J 1989;261:211-8.
49. Dorbala S, Di Carli MF, Delbeke D, Abbara S, DePuey EG, Dilsizian V. SNMMI/ASNC/SCCT guideline for cardiac SPECT/CT and PET/CT 1.0. J Nucl Med 2013;54:1485-507.
50. 18F-FDG use in inflammation and infection. J Nucl Med 2013;54:647-58.
51. 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. EJNMMI Res 2014;4:1.
52. (1)(8)F-FDG PET imaging. J Nucl Med 2015;57:568-73.
53. (18)F-FDG PET. J Nucl Med 2003;44:1030-6.
54. 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005;26:1538-43.
55. 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004;45:1989-98.
56. (1)(8)F-fluorodeoxyglucose positron emission tomography? Circ Cardiovasc Imaging 2013;6:617-26.
57. 18F-FDG PET–CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009;16:801-10.
58. Tahara N, Tahara A, Nitta Y, Kodama N, Mizoguchi M, Kaida H. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging 2010;3:1219-28.
59. (1)(8)F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol 2013;21:166-74.
60. 18F-fluorodeoxyglucose positron emission tomography in cardiac sarcoidosis. J Nucl Cardiol 2014;21:940-3.
61. Chapelon-Abric C, de Zuttere D, Duhaut P, Veyssier P, Wechsler B, Huong DL. Cardiac sarcoidosis: A retrospective study of 41 cases. Medicine (Baltim) 2004;83:315-34.
62. Le GD, Menad F, Faraggi M, Weinmann P, Battesti JP, Valeyre D. Myocardial sarcoidosis. Clinical value of technetium-99m sestamibi tomoscintigraphy. Chest 1994;106:1675-82.
63. Dilsizian V. Highlights from the updated joint ASNC/SNMMI PET myocardial perfusion and metabolism clinical imaging guidelines. J Nucl Med 2016;57:1327-8.
64. Holly TA, Abbott BG, Al-Mallah M, Calnon DA, Cohen MC, DiFilippo FP. Single photon-emission computed tomography. J Nucl Cardiol 2010;17:941-73.
65. Sciagra R, Passeri A, Bucerius J, Verberne HJ, Slart RH, Lindner O. Clinical use of quantitative cardiac perfusion PET: Rationale, modalities and possible indications. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM). Eur J Nucl Med Mol Imaging 2016;43:1530-45.
66. Verberne HJ, Acampa W, Anagnostopoulos C, Ballinger J, Bengel F, De BP. EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 Revision. Eur J Nucl Med Mol Imaging 2015;42:1929-40.
67. Kapur A, Latus KA, Davies G, Dhawan RT, Eastick S, Jarritt PH. A comparison of three radionuclide myocardial perfusion tracers in clinical practice: The ROBUST study. Eur J Nucl Med Mol Imaging 2002;29:1608-16.
68. Berman JS, Govender P, Ruberg FL, Mazzini M, Miller EJ. Scadding revisited: A proposed staging system for sardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2014;31:2-5.
69. 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008;35:933-41.
70. 18F-FDG PET in the diagnosis of cardiac sarcoidosis: A systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012;53:241-8.
71. Okada DR, Bravo PE, Vita T, Agarwal V, Osborne MT, Taqueti VR. Isolated cardiac sarcoidosis: A focused review of an under-recognized entity. J Nucl Cardiol 2016 (Epub ahead of print).
72. 18F-FDG PET for diagnosis of cardiac sarcoidosis. Kaku Igaku 1999;36:341-8.
73. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc Magn Reson 2013;15:91.
74. (18)F-FDG positron emission tomography manifestations and regional response to corticosteroid therapy in newly diagnosed cardiac sarcoidosis with complete heart block. Heart Rhythm 2015;12:2477-85.
75. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance imaging (CMR) protocols, Society for Cardiovascular Magnetic Resonance: Board of Trustees Task Force on Standardized Protocols. J Cardiovasc Magn Reson 2008;10:35.
76. Greulich S, Deluigi CC, Gloekler S, Wahl A, Zurn C, Kramer U. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 2013;6:501-11.
77. Nagai T, Kohsaka S, Okuda S, Anzai T, Asano K, Fukuda K. Incidence and prognostic significance of myocardial late gadolinium enhancement in patients with sarcoidosis without cardiac manifestation. Chest 2014;146:1064-72.
78. Patel AR, Klein MR, Chandra S, Spencer KT, Decara JM, Lang RM. Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: An observational study. Eur J Heart Fail 2011;13:1231-7.
79. Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Cheriex EC, Gorgels AP. The additional value of gadolinium-enhanced MRI to standard assessment for cardiac involvement in patients with pulmonary sarcoidosis. Chest 2005;128:1629-37.
80. Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Dassen WR, Gorgels AP. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005;45:1683-90.
81. Watanabe E, Kimura F, Nakajima T, Hiroe M, Kasai Y, Nagata M. Late gadolinium enhancement in cardiac sarcoidosis: Characteristic magnetic resonance findings and relationship with left ventricular function. J Thorac Imaging 2013;28:60-6.
82. Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969-77.
83. Murtagh G, Laffin LJ, Beshai JF, Maffessanti F, Bonham CA, Patel AV. Prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: Risk stratification using cardiovascular magnetic resonance. Circ Cardiovasc Imaging 2016;9:e003738.
84. Hulten E, Agarwal V, Cahill M, Cole G, Vita T, Parrish S. Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected cardiac sarcoidosis is associated with adverse cardiovascular prognosis: A systematic review and meta-analysis. Circ Cardiovasc Imaging 2016;9:e005001.
85. Shimada T, Shimada K, Sakane T, Ochiai K, Tsukihashi H, Fukui M. Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. Am J Med 2001;110:520-7.
86. Yang Y, Safka K, Graham JJ, Roifman I, Zia MI, Wright GA. Correlation of late gadolinium enhancement MRI and quantitative T2 measurement in cardiac sarcoidosis. J Magn Reson Imaging 2014;39:609-16.
87. Murphy RC, Hammarstrom S, Samuelsson B. Leukotriene C: A slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci USA 1979;76:4275-9.
88. Vignaux O, Dhote R, Duboc D, Blanche P, Dusser D, Weber S. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: A 1-year follow-up study. Chest 2002;122:1895-901.
89. Ardehali H, Howard DL, Hariri A, Qasim A, Hare JM, Baughman KL. A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J 2005;150:459-63.
90. Ratner SJ, Fenoglio JJ Jr, Ursell PC. Utility of endomyocardial biopsy in the diagnosis of cardiac sarcoidosis. Chest 1986;90:528-33.
91. Kandolin R, Lehtonen J, Graner M, Schildt J, Salmenkivi K, Kivisto SM. Diagnosing isolated cardiac sarcoidosis. J Intern Med 2011;270:461-8.
92. Nery PB, Keren A, Healey J, Leug E, Beanlands RS, Birnie DH. Isolated cardiac sarcoidosis: establishing the diagnosis with electroanatomic mapping-guided endomyocardial biopsy. Can J Cardiol 2013;29:1015.e1-3.
93. Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States: A Delphi study. Chest 2012;141:154-62.
94. Cain MA, Metzl MD, Patel AR, Addetia K, Spencer KT, Sweiss NJ. Cardiac sarcoidosis detected by late gadolinium enhancement and prevalence of atrial arrhythmias. Am J Cardiol 2014;113:1556-60.
95. Nadel J, Lancefield T, Voskoboinik A, Taylor AJ. Late gadolinium enhancement identified with cardiac magnetic resonance imaging in sarcoidosis patients is associated with long-term ventricular arrhythmia and sudden cardiac death. Eur Heart J Cardiovasc Imaging 2015;16:634-41.
96. Ise T, Hasegawa T, Morita Y, Yamada N, Funada A, Takahama H. Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis. Heart 2014;100:1165-72.
97. Betensky BP, Tschabrunn CM, Zado ES, Goldberg LR, Marchlinski FE, Garcia FC. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm 2012;9:884-91.
98. Schuller JL, Zipse M, Crawford T, Bogun F, Beshai J, Patel AR. Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol 2012;23:925-9.
99. Blankstein R, Waller AH. Evaluation of known or suspected cardiac sarcoidosis. Circ Cardiovasc Imaging 2016;9:e000867.
100. Hulten E, Aslam S, Osborne M, Abbasi S, Bittencourt MS, Blankstein R. Cardiac sarcoidosis—State of the art review. Cardiovasc Diagn Ther 2016;6:50-63.
101. Schneider S, Batrice A, Rischpler C, Eiber M, Ibrahim T, Nekolla SG. Utility of multimodal cardiac imaging with PET/MRI in cardiac sarcoidosis: Implications for diagnosis, monitoring and treatment. Eur Heart J 2014;35:312.
102. Wada K, Niitsuma T, Yamaki T, Masuda A, Ito H, Kubo H. Simultaneous cardiac imaging to detect inflammation and scar tissue with F-fluorodeoxyglucose PET/MRI in cardiac sarcoidosis. J Nucl Cardiol 2015. doi:10.1007/s12350-015-0348-4.
103. Harisankar CN, Mittal BR, Agrawal KL, Abrar ML, Bhattacharya A. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG uptake. J Nucl Cardiol 2011;18:926-36.